biota wins a us patent for treatment of cancer, page-141

USPTO issued US Patent 8,119,607 (the “’607 patent”) to Biota Holdings Limited containing a claim that covers the structure of BCX5191, a BioCryst discovered nucleoside analog hepatitis C viral RNA polymerase (NS5B) inhibitor. The Biota ‘607 patent was filed almost 18 months later than BioCryst’s patent application which specifically claims and discloses BCX5191, and is still pending at the USPTO. At least with respect to the hepatitis C inhibitor BCX5191 discovered and being developed by BioCryst, the Company believes the Biota patent was improvidently granted by the USPTO. Because BioCryst filed its patent application prior to Biota’s filing, BioCryst expects to be the senior party in the process at the USPTO and expects to prevail. BioCryst intends to pursue its interests vigorously to seek a resolution. BioCryst has hired the Finnegan law firm as its legal counsel to represent it before the USPTO.

USPTO is archaic but searchable http://patft.uspto.gov/netahtml/PTO/search-bool.html


Granted patent http://tiny.cc/3kctbw
Bicyclic nucleosides and nucleotides as therapeutic agents
Abstract
The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.

Maybe related
Sept 11 2007
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=9&f=G&l=50&d=PTXT&p=1&p=1&S1=(Biota+AND+Cook)&OS=Biota+AND+Cook&RS=(Biota+AND+Cook)
Tricyclic nucleosides or nucleotides as therapeutic agents


Abstract
Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.